Scientific Sessions 2025  /  Groundbreaking Trials in Cardiometabolic Therapeutics  /  Discussant
Logo

American Heart Association

  47
  0

Final ID:

Discussant

  • Lingvay, Ildiko  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Rosenson, Robert  ( MT SINAI SCHOOL MEDICINE , New York , New York , United States )
    • Author Disclosures:
    Ildiko Lingvay: DO have relevant financial relationships ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Consultant:Betagenon:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:Alveus Therapeutics:Active (exists now) ; Consultant:Altimmune:Active (exists now) ; Consultant:AbbVie:Active (exists now) ; Research Funding (PI or named investigator):Roche:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Lilly:Active (exists now) ; Research Funding (PI or named investigator):Dexcom:Active (exists now) | Robert Rosenson: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Consultant:Intercept Pharmaceuticals:Past (completed) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Editas Medicine:Past (completed) ; Consultant:CRISPER Therapeutics:Past (completed) ; Consultant:Arrowhead:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Shanghai Argo Biopharmaceutical Co.:Active (exists now) ; Research Funding (PI or named investigator):89Bio:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Past (completed) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Groundbreaking Trials in Cardiometabolic Therapeutics

Saturday, 11/08/2025 , 08:30AM - 09:45AM

Late-Breaking Science

More abstracts on this topic:
The Next Era in Cardiometabolic Treatment

Ballantyne Christie

Olezarsen in Patients with Severe Hypertriglyceridemia: The CORE-TIMI 72a and CORE2-TIMI 72b Trials

Marston Nicholas, Zhang Shuanglu, Goodrich Erica, Murphy Sabina, Xia Shuting, Li Dan, Tsimikas Sotirios, Giugliano Robert, Sabatine Marc, Bergmark Brian, Alexander Vickie, Prohaska Thomas, Kang Yu Mi, Moura Filipe, Zimerman Andre, Waldman Elaine, Weinland Julia

More abstracts from these authors:
ANGPTL3 inhibitors for reduction of cardiovascular disease risk

Rosenson Robert

How do we SELECT incretin analogues and SUSTAIN their impact? Clinical approaches for short and long-term obesity care

Jastreboff Ania, Lingvay Ildiko

You have to be authorized to contact abstract author. Please, Login
Not Available